Brief: Calliditas Therapeutics: EC Grants Conditional Approval Of Kinpeygo
15/07/2022 16:06
July 15 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* EUROPEAN COMMISSION APPROVES KINPEYGO FOR ADULTS WITH
PRIMARY
IGA NEPHROPATHY
* EUROPEAN COMMISSION (EC) HAS GRANTED CONDITIONAL MARKETING
AUTHORIZATION FOR KINPEYGO
Source text for Eikon: ID:nWkr4kd5PQ
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations